Physician profile
Stephen Voyce
NPI 1972593366
$81,481.15
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41K · 2020: $22K · 2021: $3,217 · 2022: $14K · 2023: $1,456 · 2024: $121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $776 · Food and Beverage: $487 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $250 · Education: $64.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $776.06 |
| Food and Beverage | $486.85 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $250.00 |
| Education | $64.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $40,525.67 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $23,116.78 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $12,561.63 | 2020-2023 | Farxiga |
| Novartis Pharmaceuticals Corporation | $3,481.33 | 2019-2023 | |
| Janssen Research & Development, LLC | $1,118.97 | 2023 | |
| Amgen INC. | $367.43 | 2022-2024 | Repatha |
| Sanofi-Aventis U.S. LLC | $124.99 | 2021 | |
| Novo Nordisk INC | $64.54 | 2023 | Wegovy |
| Medtronic, INC. | $42.40 | 2021 | |
| Boston Scientific Corporation | $30.87 | 2019 | |
| Medtronic Vascular, INC. | $29.04 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.50 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Voyce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.